Izrael -
hebrejština -
Ministry of Health
סנטה - קרם לילה עם זהב וקולגן
ביסקול בעמ - שיפור מראה העור
Izrael -
hebrejština -
Ministry of Health
טוברקס 2 איקס
novartis israel ltd - tobramycin - טיפות עיניים - tobramycin 0.3 % - tobramycin - tobramycin - antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to tobramycin.
Izrael -
hebrejština -
Ministry of Health
לה רוש פוזה טולריאן פלואיד תחליב לחות והגנה לעור הפנים
אינטרביוטי קוסמטיקס ישראל בעמ - לחות והגנה לעור הפנים
Izrael -
hebrejština -
Ministry of Health
לה רוש פוזה טולריאן ריץ' לחות והגנה לעור פנים עם נטייה ליובש
אינטרביוטי קוסמטיקס ישראל בעמ - לחות והגנה לעור
Izrael -
hebrejština -
Ministry of Health
אלוריל 300
dexcel ltd, israel - allopurinol - טבליה - allopurinol 300 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Izrael -
hebrejština -
Ministry of Health
אלוריל 100
dexcel ltd, israel - allopurinol - טבליה - allopurinol 100 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.